OTLK: A Story — The World’s Most-Used Eye Drug Is Not Approved for the Eye

01The puzzle: a drug everyone uses and no one approved

Here is a fact that reads like a typo: the world’s most-used drug for one of the leading causes of blindness in older adults is not approved for that use. Millions of injections a year, worldwide, with a medicine no regulator ever authorized for the eye. It is not a mistake. It is one of the most instructive cases of how the drug market actually works — and we will use Outlook Therapeutics ($OTLK) as the worked example to understand it.

The disease is neovascular (wet) age-related macular degeneration: abnormal blood vessels grow under the retina and, untreated, steal central vision. It is controlled with injections of “anti-VEGF” drugs directly into the eye. The drug ophthalmologists reach for most often is bevacizumab, whose brand name is Avastin — a cancer drug, repurposed “off-label” for the eye for two decades.

It is worth pausing on what is at stake for the patient, because it is what makes the whole economics real. Wet AMD does not hurt and does not kill: it quietly removes the center of vision — faces, words on a page, the step in front of you — leaving only peripheral sight. Untreated, in many it leads to legal blindness. The treatment is not a pill: it is an injection into the eye, repeated every four to eight weeks, often for years. Multiply those injections by millions of patients and by the difference between $50 and $2,000 per dose, and you see why the choice of drug is not a technical footnote: it is one of the heaviest line items in Western healthcare spending.

02The price paradox: $50 versus $2,000

Start with the number that explains everything. A dose of off-label Avastin for the eye costs about $50-100 (in 2022, on average, roughly $62 per treatment in the United States). The branded drugs approved for the same disease cost a fortune more: Lucentis about $1,228, Eylea about $1,641, with list prices reaching around $2,000. That is a twenty-to-thirty-fold gap to treat the same condition.

And here comes the part that breaks common sense: it works. A landmark public trial, CATT (2011), showed Avastin is comparable to Lucentis in treating wet AMD. The World Health Organization lists it among essential medicines. It is not a poor person’s fallback: it is the rational choice of thousands of doctors worldwide, who spend a fraction for a comparable result.

03Why no one ever approved it (and what changes if you do)

The answer is a small market failure, and it is illuminating. Getting a drug approved costs hundreds of millions: clinical trials, compliant manufacturing, regulatory dossiers. No one spends that without expecting to recoup it through sales. But bevacizumab for the eye is, in effect, almost a generic: you buy the oncology Avastin and “repackage” it in a pharmacy into small doses. There is no company that can sell it at a premium. So no one ever had the economic incentive to get it approved for the eye — and it stayed off-label for twenty years. The maker of the branded drugs, who profits from the expensive alternatives, certainly had no reason to.

This is why Outlook’s attempt is unusual: it is doing the thing no one wanted to do. And to judge whether it makes sense, you have to ask what an approval actually adds to a drug that is already in use:

There is a detail that makes that market failure more than an academic curiosity: safety. Because Avastin for the eye is split into mini-doses by pharmacies that compound bespoke batches, the chain lacks the control of a sterile industrial product. In the past there have been outbreaks of serious eye infections (endophthalmitis) tied to contaminated compounded batches. These are rare events, but when they happen they can cost sight. It is exactly the kind of risk an approved product, with compliant manufacturing and surveillance, is designed to reduce — and it is one of the strongest arguments for LYTENAVA.

• Standardized manufacturing. Today every pharmacy compounds its own dose. An approved version (LYTENAVA) is a uniform industrial product, vial by vial.
• Safety and no contamination. Pharmacy repackaging has in the past caused serious eye-infection incidents. A sterile product approved for ophthalmic use lowers that risk.
• FDA labeling and pharmacovigilance. An official indication, approved dosing, adverse-event monitoring — and a different liability profile for the physician.

04The regulatory saga: rejected at home, approved in Europe

Outlook’s road has been anything but straight, and that is part of the story. In the United States the application drew more than one Complete Response Letter (the FDA’s “no, not yet”), tied mainly to manufacturing and data questions rather than doubts about efficacy. The turning point was a won appeal: the FDA’s Office of New Drugs concluded that effectiveness is established and no further trials are needed, directing the parties to settle the label wording. Outlook then resubmitted in June 2026, accepted as a Class 1 review, with a decision due July 29, 2026.

Meanwhile, outside the United States, the story is further along. LYTENAVA (bevacizumab gamma) received European Commission marketing authorization in May 2024 — the first and only authorized ophthalmic formulation of bevacizumab in the EU and UK, with ten years of market exclusivity — followed by a NICE recommendation in the UK and a commercial launch in Germany and the UK in June 2025. For global distribution, Outlook partnered with Cencora (formerly AmerisourceBergen). So the drug is not theory: in Europe it is already on the shelf.

Two things deserve underlining. First: the ten-year European market exclusivity is unusual and valuable — it protects LYTENAVA from direct competition by other ophthalmic bevacizumab versions across an entire continent, giving Outlook a window to build adoption without immediate copies. Second: the United States remains the biggest prize. The U.S. anti-VEGF market is worth billions a year, and it is where the gap between do-it-yourself and brands is most glaring — so it is where an FDA approval would matter most. That is why the July 29 date, technical as it is (it turns on labeling and manufacturing), weighs so heavily on the stock.

05The nuance that makes you think

Here is why the case is fascinating rather than trivial: it contains two real tensions.

Hold the two paradoxes together and you have the honest case: a compelling thesis (finally approving the right drug in a huge market) tied to two hard enemies — the $50 competitor and its own bank account.

There is also a hidden engine that will decide a lot: reimbursement. In the United States the public system pays for both off-label Avastin and the expensive brands, and the way doctors are reimbursed for the drug they inject heavily influences which one they pick. An approved product with its own billing code can change that equation — in both directions. If reimbursement makes LYTENAVA as attractive to the practice as, or more than, the compounded route, adoption can accelerate; if it stays disadvantaged versus the $50 option, the price wall holds. It is the sort of boring, invisible detail that, in this market, matters more than any press release.

06The tool: how to read an “off-label / repurposed drug” case

Here is the gift to keep. Next time you read about a company trying to approve an “already-used” drug — an old active ingredient, a repurposed generic, a widespread off-label use — run it through four questions:

1. Is there proven off-label demand? If doctors already use it, half the commercial risk (does it work? do they want it?) is already resolved.
2. What does approval add? Safety, consistency, labeling, reimbursement, liability: how much, concretely, is that package worth?
3. Can it price above the cheap version and still win? This is the decisive question: is the price corridor between do-it-yourself and premium brands wide enough to fit inside?
4. Does it have the cash to reach commercialization? Approval and survival are two different things: look at cash, burn and dilution before falling in love with the thesis.

07The map of the neighbors

To orient yourself, here is who is in the retinal anti-VEGF market. These are not recommendations: they are the names you will see recur, and knowing where each sits makes every future headline readable.

Notice the pattern: the market lines up along a single axis — price — from the $50 do-it-yourself to the thousand-dollar brands. Outlook is trying to plant a flag in the middle. That axis explains almost every headline in the space.

08Risks: what still has to be proven

• Going concern and dilution. This is risk number one: the company has flagged doubts about its 12-month cash and finances at very low prices; every raise thins existing holders.
• The off-label price wall. Convincing doctors and payers to pay more than the $50 do-it-yourself is not a given, and will define real peak sales.
• July 29 FDA outcome. It is a binary event: despite the won efficacy appeal, label wording and manufacturing still have to be settled.
• Competition on all fronts. Long-acting brands (Eylea HD, Vabysmo), a biosimilar wave and Avastin itself: the market is crowded and moving.
• Commercial execution. The European launch still has to translate into real revenue; the Cencora distribution model must prove adoption.

09Bottom line

“OTLK: A Story” is not, in the end, a story about an eye drug. It is the story of a twenty-year market failure — the right drug, effective and cheap, never approved because no one profited enough — and of a small company finally trying to fill it. Outlook is a rich example because it lays bare the difference between it works, it is approved, and it is a business: three different things, and this case keeps all three on the table at once.

The takeaway is not a verdict on the stock. It is a lens: next time you meet an “already-used” drug someone wants to approve, you will be able to take it apart yourself — proven demand, the added value of approval, the price corridor, and the cash to get there. It is a skill that keeps working long after this PDUFA has passed.